Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rabbit antithymocyte immunoglobulin, quantity: 25 mg - injection, powder for - excipient ingredients: sodium chloride; glycine; mannitol - thymoglobuline (rabbit anti-human thymocyte immunoglobulin) is indicated for the prophylaxis of graft rejection in renal transplantation; treatment of steroid-resistant or moderate to severe renal transplant rejection: and treatment of refractory or relapsing aplastic anaemia.

Malta - English - Malta Medicines Authority

bio products laboratory limited dagger lane, elstree hertfordshire, wd6 3bx, united kingdom - immunoglobulin rabies, human - solution for injection - immunoglobulin rabies, human 150 iu/ml - immune sera and immunoglobulins

Israel - English - Ministry of Health

sanofi israel ltd - immunoglobulin rabbit anti-human thymocyte - powder for concentrate for solution for infusion - immunoglobulin rabbit anti-human thymocyte 25 mg/vial - antithymocyte immunoglobulin (rabbit) - antithymocyte immunoglobulin (rabbit) - immunosuppression in transplantation: prevention and treatment of graft rejection. treatment of acute graft versus host disease (gvhd). hematology treatment of aplastic anemia.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sanofi b.v. - anti-t lymphocyte rabbit immunoglobulin for human use 25 mg - powder for solution for infusion - 5 mg/ml - human anti-thymocyte immunoglobulin (origin rabbits) 25 mg - antithymocyte immunoglobulin (rabbit)

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - equine antithymocyte immunoglobulin, quantity: 50 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; glycine; hydrochloric acid - indications as at 11 april 2002 : atgam is indicated for renal transplant patients in whom reduction of peripheral t-lympocyte function as measured by rosette-forming cell assay could be desirable. during controlled clinical trials, this immunosuppression has been demonstrated in renal allograft recipients treated with atgam. when it was administered prophylactically with conventional immunosuppressive therapy, atgam delayed the onset of the first rejection episode, and when it was administered at the time of the first rejection, atgam resolved the acute rejection episode more frequently than did conventional therapy alone.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - antithymocyte immunoglobulin 25mg (rabbit) - powder for infusion - 25 mg - active: antithymocyte immunoglobulin 25mg (rabbit) excipient: glycine mannitol sodium chloride - thymoglobuline® (rabbit anti - human thymocyte immunoglobulin) is indicated for the prophylaxis of graft rejection in renal transplantation; treatment of steroid - resistant or moderate to severe renal transplant rejection and in the prophylaxis of graft rejection in heart transplantation.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

neovii biotech gmbh - anti-t lymphocyte rabbit immunoglobulin for human use 20 mg/ml - concentrate for solution for infusion - 20 mg/ml - human anti-t-lymphocyte immunoglobulin (origin rabbits) 20 mg/ml - antithymocyte immunoglobulin (rabbit)

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - anti-t lymphocyte immunoglobulin for human use, horse - concentrate for solution for infusion - antilymphocyte immunoglobulin (horse)

Ireland - English - HPRA (Health Products Regulatory Authority)

genzyme europe b.v. - rabbit anti-human thymocyte immunoglobulin - powder for solution for infusion - 25 milligram(s) - selective immunosuppressants; antithymocyte immunoglobulin (rabbit)

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - antithymocyte immunoglobulin 50 mg/ml (equine) - concentrate for injection - 250 mg/5ml - active: antithymocyte immunoglobulin 50 mg/ml (equine) excipient: glycine hydrochloric acid sodium hydroxide water for injection - atgam is indicated for the management of allograft rejection, including delay of onset of first rejection episode, in patients who have undergone renal transplantation.